BioSpace News Archive

Alphatec Holdings, Inc. announced its intention to offer, subject to market and other conditions, $250,000,000 aggregate principal amount of convertible senior notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that it will present at the following upcoming virtual investor conferences:

vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs.

SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, reported second quarter 2021 financial results and recent portfolio updates.

The controlled use of pesticides is an important tool for the agricultural sector.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to prevent COVID-19 infection among household contacts of SARS-CoV-2 infected individuals.

BridgeBio Pharma, Inc. announced that on August 3, 2021, the compensation committee of BridgeBio’s board of directors granted 17 new employees restricted stock units for an aggregate of 21,414 shares of the Company’s common stock.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update.

Rapid Micro Biosystems, Inc. announced that the underwriters of its previously announced initial public offering of Class A common stock have exercised their option to purchase additional shares in part for 1,086,604 shares at the public offering price of $20.00 per share less underwriting discounts and commissions, for additional gross proceeds to Rapid Micro of $21.7 million.

Tarsus Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced financial results and provided business and clinical updates for the quarter ended June 30, 2021.